Format

Send to

Choose Destination
Adv Drug Deliv Rev. 2017 Nov 1;121:3-8. doi: 10.1016/j.addr.2017.05.016. Epub 2017 Jun 9.

Pathophysiology of liver fibrosis and the methodological barriers to the development of anti-fibrogenic agents.

Author information

1
University College London - Institute for Liver and Digestive Health, Royal Free Hospital, NW3 2PF London, United Kingdom.
2
University College London - Institute for Liver and Digestive Health, Royal Free Hospital, NW3 2PF London, United Kingdom. Electronic address: m.pinzani@ucl.ac.uk.

Abstract

Liver fibrosis and cirrhosis resulting from long-standing liver damage represents a major health care burden worldwide. To date, there is no anti-fibrogenic agent available, making liver transplantation the only curative treatment for decompensated cirrhotic liver disease. Liver fibrosis can result from different underlying chronic liver disease, such as chronic viral infection, excessive alcohol consumption, fatty liver disease or autoimmune liver diseases. It is becoming increasingly recognised that as a result from different pathogenic mechanisms liver fibrosis must be considered as many different diseases for which individual treatment strategies need to be developed. Moreover, the pathogenic changes of both liver architecture and vascularisation in cirrhotic livers, as well as the lack of "true-to-life" in vitro models have impeded the development of an effective anti-fibrogenic drug. Thus, in order to identify an efficient anti-fibrogenic compound, novel in-vitro models mimicking the interplay between pro-fibrogenic cell populations, immune cells and, importantly, the extracellular matrix need to be developed.

KEYWORDS:

Anti-fibrotic drug; Chronic liver disease (CLD); Drug development; Hepatic stellate cells (HSC); In-vitro models; Liver fibrosis

PMID:
28600202
DOI:
10.1016/j.addr.2017.05.016
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center